Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

8.21USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$8.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
372,605
52-wk High
$11.06
52-wk Low
$4.32

Chart for

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $525.23
Shares Outstanding(Mil.): 63.59
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 28.91 32.89
EPS (TTM): -0.39 -- --
ROI: -2.02 13.55 13.14
ROE: -7.53 15.38 15.15

BRIEF-Starboard Value Cuts Stake In Depomed Inc To 4.3 Pct

* STARBOARD VALUE LP CUTS STAKE IN DEPOMED INC TO 4.3 PERCENT AS OF MAY 18 FROM PREVIOUS STAKE OF 6.1 PERCENT AS OF MAY 10 - SEC FILING Source text: (https://bit.ly/2J3k2sc) Further company coverage:

May 22 2018

BRIEF-Starboard Value Lp Reports 6.1 Pct Stake In Depomed Inc As Of May 10, 2018

* STARBOARD VALUE LP REPORTS 6.1 PERCENT STAKE IN DEPOMED INC AS OF MAY 10, 2018 - SEC FILING

May 14 2018

BRIEF-Depomed Q1 Earnings Per Share $0.48

* Q1 EARNINGS PER SHARE VIEW $0.17 -- THOMSON REUTERS I/B/E/S

May 10 2018

BRIEF-Depomed Appoints Stan Bukofzer As Chief Medical And Scientific Officer

* DEPOMED ANNOUNCES THE APPOINTMENT OF STAN BUKOFZER, M.D. AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL AND SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

Apr 02 2018

BRIEF-Depomed Inc Files For Mixed Shelf Of Up To $300 Million‍​

* DEPOMED INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2oD3GLe) Further company coverage:

Mar 02 2018

BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52

* ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

Earnings vs. Estimates